CVE:KNE Kane Biotech (KNE) Stock Price, News & Analysis C$0.10 0.00 (0.00%) (As of 12/20/2024 05:17 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsHeadlinesInsider Trades About Kane Biotech Stock (CVE:KNE) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Kane Biotech alerts:Sign Up Key Stats Today's RangeC$0.10▼C$0.1050-Day RangeC$0.10▼C$0.1452-Week RangeC$0.07▼C$0.17Volume18,500 shsAverage Volume124,197 shsMarket CapitalizationC$13.25 millionP/E RatioN/ADividend Yield3.08%Price TargetN/AConsensus RatingN/A Company OverviewKane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections. It offers revyve, an antimicrobial wound gel; and shampoos, shampoo bars, and scalp detoxifiers under the DermaKB brand. The company is also developing coactiv+ Antimicrobial Surgical Hydrogel for use in surgical/acute wounds; coactiv+ Antimicrobial Wound Rinse for use in acute and chronic wounds; coactiv+ Antimicrobial Wound Gel Spray for use in acute, chronic wounds, and first and second degree burns; and DispersinB Hydrogel for prosthetic joint infection. Kane Biotech Inc. was incorporated in 2001 and is based in Winnipeg, Canada.Read More… Receive KNE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kane Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address KNE Stock News HeadlinesKane Biotech Announces Change in US Distribution Partner for revyve(TM) Antimicrobial Wound GelNovember 28, 2024 | stockhouse.comKane Biotech Announces Health Canada Approval of revyve™ Antimicrobial Wound GelNovember 14, 2024 | markets.businessinsider.comTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… December 22, 2024 | Crypto 101 Media (Ad)Kane Biotech Provides Investor Update Following FB Dermatology Acquisition AnnouncementNovember 14, 2024 | markets.businessinsider.comKane Biotech Announces Agreement to Acquire FB DermatologyNovember 12, 2024 | markets.businessinsider.comKane Biotech Announces Donation of revyve™ Antimicrobial Wound Gel to UkraineOctober 23, 2024 | markets.businessinsider.comPositive Signs As Multiple Insiders Buy Kane Biotech StockOctober 21, 2024 | finance.yahoo.comKane Biotech to distribute XSONX Wound Hygiene SystemOctober 19, 2024 | msn.comSee More Headlines KNE Stock Analysis - Frequently Asked Questions How have KNE shares performed this year? Kane Biotech's stock was trading at C$0.08 at the start of the year. Since then, KNE shares have increased by 25.0% and is now trading at C$0.10. View the best growth stocks for 2024 here. How do I buy shares of Kane Biotech? Shares of KNE stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. What other stocks do shareholders of Kane Biotech own? Based on aggregate information from My MarketBeat watchlists, some other companies that Kane Biotech investors own include Mason Resources (LLG), Datametrex AI (DM) and Allstar Health Brands (ALST). Industry, Sector and Symbol Stock ExchangeCVE SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolCVE:KNE CUSIPN/A CIKN/A Webwww.kanebiotech.com Phone+1-204-4531301FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)C($0.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeC$-5,480,000.00 Net Margins637.45% Pretax MarginN/A Return on EquityN/A Return on Assets-58.43% Debt Debt-to-Equity Ratio1,164.24 Current Ratio0.82 Quick Ratio0.39 Sales & Book Value Annual SalesC$2.74 million Price / Sales4.84 Cash FlowC$0.01 per share Price / Cash Flow8.50 Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares132,510,000Free FloatN/AMarket CapC$13.25 million OptionableNot Optionable Beta0.52 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report This page (CVE:KNE) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kane Biotech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kane Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.